Aurobindo Pharma has confirmed on the matter which involved recall of 2,820 bottles of Metoprolol tartrate tablets in the US market, and the recall was done at the pharmacy level. As the matter was not material in nature, the same did not warrant disclosure to the Stock Exchanges, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.